Xencor (NASDAQ:XNCR) Price Target Increased to $36.00 by Analysts at Wedbush

Xencor (NASDAQ:XNCR - Get Free Report) had its price objective increased by analysts at Wedbush from $34.00 to $36.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm presently has an "outperform" rating on the biopharmaceutical company's stock. Wedbush's price objective would suggest a potential upside of 60.14% from the stock's previous close.

Other equities analysts have also recently issued reports about the company. StockNews.com upgraded Xencor from a "sell" rating to a "hold" rating in a report on Saturday, March 9th. Mizuho decreased their price objective on Xencor from $59.00 to $50.00 and set a "buy" rating for the company in a research note on Monday, January 22nd. Royal Bank of Canada reiterated an "outperform" rating and issued a $32.00 price objective on shares of Xencor in a research note on Wednesday, February 28th. BTIG Research decreased their price objective on Xencor from $56.00 to $38.00 and set a "buy" rating for the company in a research note on Tuesday, April 16th. Finally, Piper Sandler reiterated a "neutral" rating and issued a $24.00 price objective (down previously from $37.00) on shares of Xencor in a research note on Wednesday, February 28th. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, Xencor has a consensus rating of "Moderate Buy" and an average target price of $36.25.

Xencor Trading Down 4.5 %

Shares of NASDAQ XNCR traded down $1.06 during trading on Friday, reaching $22.48. The stock had a trading volume of 471,061 shares, compared to its average volume of 699,155. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.36 and a current ratio of 7.36. The company has a market cap of $1.39 billion, a P/E ratio of -10.70 and a beta of 0.77. Xencor has a fifty-two week low of $16.49 and a fifty-two week high of $28.96. The business's 50-day moving average price is $21.84 and its 200-day moving average price is $20.62.

Xencor (NASDAQ:XNCR - Get Free Report) last announced its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($1.11) EPS for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.28). Xencor had a negative net margin of 74.90% and a negative return on equity of 18.67%. The firm had revenue of $12.80 million for the quarter, compared to analysts' expectations of $23.07 million. During the same quarter last year, the business earned ($1.02) earnings per share. The business's revenue was down 32.3% compared to the same quarter last year. On average, equities research analysts predict that Xencor will post -3.25 EPS for the current fiscal year.

Insiders Place Their Bets

In other Xencor news, VP John R. Desjarlais sold 1,280 shares of Xencor stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $23.50, for a total transaction of $30,080.00. Following the transaction, the vice president now owns 186,433 shares of the company's stock, valued at $4,381,175.50. The transaction was disclosed in a filing with the SEC, which is available at this link. In other news, VP John R. Desjarlais sold 54,108 shares of the business's stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $19.38, for a total value of $1,048,613.04. Following the transaction, the vice president now owns 161,675 shares of the company's stock, valued at $3,133,261.50. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP John R. Desjarlais sold 1,280 shares of the business's stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $23.50, for a total value of $30,080.00. Following the completion of the transaction, the vice president now directly owns 186,433 shares in the company, valued at approximately $4,381,175.50. The disclosure for this sale can be found here. Insiders have sold a total of 101,351 shares of company stock valued at $2,152,417 over the last quarter. Company insiders own 5.23% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. abrdn plc acquired a new position in Xencor during the fourth quarter worth $3,726,000. State of New Jersey Common Pension Fund D boosted its position in Xencor by 24.8% during the third quarter. State of New Jersey Common Pension Fund D now owns 110,353 shares of the biopharmaceutical company's stock worth $2,224,000 after purchasing an additional 21,946 shares in the last quarter. Hudson Bay Capital Management LP boosted its position in Xencor by 144.7% during the third quarter. Hudson Bay Capital Management LP now owns 232,500 shares of the biopharmaceutical company's stock worth $4,685,000 after purchasing an additional 137,500 shares in the last quarter. Deutsche Bank AG boosted its position in Xencor by 13.0% during the third quarter. Deutsche Bank AG now owns 33,098 shares of the biopharmaceutical company's stock worth $667,000 after purchasing an additional 3,805 shares in the last quarter. Finally, Diversified Trust Co purchased a new stake in Xencor during the fourth quarter worth $265,000.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.